Intrahepatic Cholestasis Management

Introduction to Evidence-Based Treatment

• The American College of Obstetricians and Gynecologists recommends ursodeoxycholic acid (UDCA) as the first-line treatment for intrahepatic cholestasis, particularly in pregnancy-related cases 1, 2, 3
• UDCA should be used as first-line therapy for maternal symptoms in intrahepatic cholestasis of pregnancy, with the goal of reducing the risk of spontaneous preterm birth and stillbirth 1, 2, 3

First-Line Therapy

• The American Association for the Study of Liver Diseases and the European Association for the Study of the Liver recommend UDCA as the only guideline-recommended pharmacological treatment for intrahepatic cholestasis 1, 2, 3
• UDCA has multiple mechanisms, including increasing hepatocyte secretory capacity, enhancing bile formation, protecting against bile acid-mediated cellular damage, and protecting fetal cardiac myocytes from arrhythmia 3

Alternative Symptomatic Therapies

• Rifampicin, cholestyramine, guar gum, and activated charcoal may be considered for pruritus, though evidence supporting their use is limited 2, 3
• These are second-line options when UDCA provides insufficient symptom relief 2

Diagnosis and Treatment Initiation

• Measure serum bile acids and liver transaminases to confirm diagnosis, and perform abdominal ultrasound to exclude extrahepatic obstruction (dilated ducts) 1, 5, 6
• Start UDCA for all confirmed cases, and monitor bile acid levels weekly from 32 weeks' gestation in pregnancy to identify concentrations >40 μmol/L 1, 2, 3

Pregnancy-Specific Management

• Plan delivery at 35-36 weeks if bile acids >100 μmol/L due to increased stillbirth risk, and deliver between 36-39 weeks if bile acids <100 μmol/L 1, 2, 3
• Administer antenatal corticosteroids if delivering before 37 weeks 1

Key Recommendations

• The Society for Maternal-Fetal Medicine recommends liver transplantation as the definitive treatment for advanced cholestatic liver disease with hepatocellular failure or portal hypertension complications 4
• The American Gastroenterological Association recommends avoiding experimental therapies like hemoadsorption when evidence-based UDCA therapy exists 1, 2, 3